AI Engines For more Details: Perplexity Kagi Labs You
Choleretic Effect: Fenipentol stimulates the secretion of bile from the liver into the bile ducts. This choleretic effect helps improve the flow of bile, which is important for digestion and the absorption of fats and fat-soluble vitamins.
Cholagogue Effect: In addition to promoting bile secretion, fenipentol also facilitates the release of bile from the gallbladder into the small intestine. This cholagogue effect aids in the digestion and emulsification of dietary fats, promoting their absorption.
Gallbladder Disorders: Fenipentol may be prescribed to individuals with certain gallbladder disorders, such as cholelithiasis (gallstones) and biliary dyskinesia (impaired gallbladder motility). By enhancing bile flow, fenipentol helps prevent the formation of gallstones and reduces symptoms associated with gallbladder dysfunction.
Digestive Disorders: Fenipentol is sometimes used as an adjunctive therapy for digestive disorders characterized by impaired bile flow, such as dyspepsia and functional dyspepsia. It can help alleviate symptoms such as bloating, indigestion, and discomfort after meals.
Liver Support: Fenipentol may provide support to individuals with certain liver conditions, such as fatty liver disease (steatosis) and liver congestion. By promoting bile production and flow, it assists in the removal of toxins and metabolic waste products from the liver.
Gastrointestinal Health: The improved bile flow facilitated by fenipentol can contribute to overall gastrointestinal health by optimizing digestion and nutrient absorption. It may help maintain regular bowel movements and prevent constipation in some individuals.
Side Effects: Common side effects of fenipentol may include gastrointestinal symptoms such as nausea, abdominal discomfort, diarrhea, and bloating. These side effects are usually mild and transient but should be reported to a healthcare provider if persistent or severe.
Contraindications: Fenipentol is contraindicated in individuals with known hypersensitivity to the medication or its components. It should not be used in patients with acute biliary obstruction or severe liver disease without medical supervision.
Drug Interactions: Fenipentol may interact with certain medications, including anticoagulants (blood thinners) and lipid-lowering agents. It is important to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
Dosage and Administration: Fenipentol is typically taken orally in the form of tablets or capsules. The dosage and frequency of administration depend on the individual's condition, severity of symptoms, and response to treatment. It is important to follow the healthcare provider's instructions and not exceed the recommended dose.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 1.3 | 0.3 | 3.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0.5 | 1.6 |
| Allergies | 0.8 | 0.7 | 0.14 |
| Allergy to milk products | 0.3 | 0.6 | -1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.4 | 1.9 | -0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | |
| Ankylosing spondylitis | 1.2 | 0.4 | 2 |
| Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
| Asthma | 2.2 | 1.3 | 0.69 |
| Atherosclerosis | 0.6 | 0.6 | 0 |
| Atrial fibrillation | 1.2 | 0.6 | 1 |
| Autism | 2.7 | 2.2 | 0.23 |
| Autoimmune Disease | 0.3 | 0.8 | -1.67 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Cancer (General) | 0.3 | 0.8 | -1.67 |
| Carcinoma | 1.7 | 1.4 | 0.21 |
| Celiac Disease | 0.6 | 1.5 | -1.5 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 1.2 | 1.3 | -0.08 |
| Chronic Kidney Disease | 1.7 | 0.6 | 1.83 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 1.2 | 1.1 | 0.09 |
| Colorectal Cancer | 1.7 | 1.1 | 0.55 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.2 | 1.1 | -4.5 |
| COVID-19 | 1.5 | 2.7 | -0.8 |
| Crohn's Disease | 2.4 | 2 | 0.2 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 0.8 | -0.8 | |
| Depression | 2.9 | 2 | 0.45 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.2 | 0.4 | -1 |
| Endometriosis | 1.2 | 0.8 | 0.5 |
| Epilepsy | 0.6 | 0.6 | 0 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 1.7 | 0.6 | 1.83 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 1.4 | -0.56 |
| gallstone disease (gsd) | 0.7 | 0.8 | -0.14 |
| Generalized anxiety disorder | 0.7 | 0.7 | 0 |
| Gout | 0.5 | 0.5 | |
| Graves' disease | 0.6 | 1.7 | -1.83 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.7 | 0.6 | 1.83 |
| Heart Failure | 0.5 | 0.8 | -0.6 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.6 | -0.6 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.2 | 1.9 | -0.58 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 1.2 | 0.3 | 3 |
| IgA nephropathy (IgAN) | 0.6 | 1 | -0.67 |
| Inflammatory Bowel Disease | 1.4 | 1.6 | -0.14 |
| Insomnia | 0.9 | 0.8 | 0.13 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 2.1 | 1.1 | 0.91 |
| ischemic stroke | 0.7 | 0.8 | -0.14 |
| Liver Cirrhosis | 2.5 | 1.7 | 0.47 |
| Long COVID | 1.7 | 2.2 | -0.29 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.2 | 0.6 | -2 |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.1 | 0.6 | -5 |
| ME/CFS without IBS | 0.5 | 1.2 | -1.4 |
| Menopause | 0.2 | 0.5 | -1.5 |
| Metabolic Syndrome | 2.7 | 2.8 | -0.04 |
| Mood Disorders | 2.4 | 1.5 | 0.6 |
| Multiple Sclerosis | 1.3 | 1.2 | 0.08 |
| Multiple system atrophy (MSA) | 0.2 | 0.3 | -0.5 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.3 | 1.5 | -4 |
| Neuropathy (all types) | 0.3 | 0.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 1.6 | 0.06 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.6 | 0.5 |
| Obesity | 3.2 | 3.1 | 0.03 |
| obsessive-compulsive disorder | 0.4 | 1.6 | -3 |
| Osteoarthritis | 0.4 | 0.6 | -0.5 |
| Osteoporosis | 1.1 | 0.9 | 0.22 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 1.8 | 2.3 | -0.28 |
| Polycystic ovary syndrome | 1.3 | 1.4 | -0.08 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.6 | 0.6 | |
| Primary sclerosing cholangitis | 0.3 | 0.2 | 0.5 |
| Psoriasis | 0.3 | 0.8 | -1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 2 | 0.15 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.4 | 1.1 | 0.27 |
| Sjögren syndrome | 0.3 | 1.3 | -3.33 |
| Sleep Apnea | 0.9 | 1.1 | -0.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.1 | 2 |
| Stress / posttraumatic stress disorder | 1.7 | 1.2 | 0.42 |
| Systemic Lupus Erythematosus | 1 | 1.7 | -0.7 |
| Tic Disorder | 0.3 | 0.9 | -2 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 0.3 | 1.7 | -4.67 |
| Type 2 Diabetes | 2.8 | 2.2 | 0.27 |
| Ulcerative colitis | 1.2 | 1.7 | -0.42 |
| Unhealthy Ageing | 1.5 | 1.1 | 0.36 |
| Vitiligo | 0.6 | 0.3 | 1 |
